Ki67 and BUBR1 may discriminate clinically insignificant prostate cancer in the psa range <4 ng/ml

Japanese Journal of Clinical Oncology

Volumn 41, Issue 4, 2011, Pages 555-564

  Nagao, Kazuhiro ^a,b   Yamamoto, Yoshiaki ^a   Hara, Tomohiko ^a   Komatsu, Hirotaka ^a   Inoue, Ryo ^a,b   Matsuda, Kenji ^a,b   Matsumoto, Hiroaki ^a,b   Hara, Takahiko ^a   Sakano, Shigeru ^a   Baba, Yoshikazu ^b   Matsuyama, Hideyasu ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shuto General Hospital   (Japan)

Author keywords

BUBR1; Clinical insignificance; Ki67; Prostate cancer

Indexed keywords

BUB1 RELATED PROTEIN; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; BIOPSY; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; WATCHFUL WAITING;

EID: 79953750859     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq233     Document Type: Article

References (28)

1. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-5.
2. Recker F, Kwiatkowski MK, Huber A, Stamm B, Lehmann K, Tscholl R. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the AARAU experience. J Urol 2001;166:851-5.
3. Babaian RJ, Jhonston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA HA, Jr. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng./ml.: relation to biopsy strategy. J Urol 2001;165:757-60.
4. Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y, et al. Prostate-specific antigen cutoff of 2.6 ng/ml for prostate cancer screening is associated with favorable pathologic tumor features. Urology 2002;60:469-74.
5. Carter HB, Epstein JI, Partin AW. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 1999;53:126-30.
6. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
7. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors: a contemporary analysis. Cancer 2004;101:2001-5.
8. Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf JB, et al. Validation of the contemporary Epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008;54:1306-13.
9. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009;55:1321-32.
10. van den Bergh RCN, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009;55:1-8.
11. Bubendorf L, Sauter G, Moch H, Schmid H-P, Gasser TC, Jordan P, et al. Ki67 labeling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996;178:437-41.
12. Bubendorf L, Tapia C, Gasser TC, Casselo R, Grunder B, Moch H, et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 1998;29:949-54.
13. Cowen D, Troncoso P, Khoo VS, Zagars GK, von Eschenbach C, Meistrich ML. Ki67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res 2002;8:1148-54.
14. Inoue T, Segawa T, Shiraishi T, Yoshida T, Toda Y, Yamada T, et al. Androgen receptor, Ki67 and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005;66:332-7.
15. Quinn DI, Henshall SM, Head DR, Golovsky D, Wilson JD, Brenner PC, et al. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res 2000;60:1585-94.
16. Pollack A, Cowen D, Troncoso P, Zagars GK, von Eschenbach AC, Meistrich ML, et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma. Cancer 2003;97:1630-8.
17. Concato J, Jain D, Li WW, Risch HA, Uchio EM, Wells CK, et al. Molecular markers and mortality in prostate cancer. BJU Int 2007;100:1259-63.
18. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999;53:707-13.
19. Scmitz M, Grignard G, Margue C, Dippel W, Capesius C, Mossong J, et al. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007;120:1284-92.
20. Presti JC, Jr, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather 6 biopsies: results of prospective clinical trial. J Urol 2000;163:163-7.
21. Yamamoto Y, Matsuyama H, Chochi Y, Okuda M, Kawauchi S, Inoue R, et al. Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer. Cancer Genet Cytogenet 2007;174:42-7.
22. Halvorsen OJ, Haukaas SA, Akslen LA. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 2003;9:1474-9.
23. Ruijter E, van de Kaa C, Aalders T, Ruiter D, Miller G, Debruyne F. Heterogenous expression of E-cadherin and p53 in prostate cancer: clinical implications. Mod Pathol 1998;11:276-81.
24. Kobayashi T, Mitsumori K, Kawahara T, Nishizawa K, Ogura K, Ide Y. Prostate cancer detection among men with prostate specific antigen levels of 2.5 to 4.0 ng/ml in a Japanese urological referral population. J Urol 2006;175:1281-5.
25. Sun L, Moul JW, Hotaling JM, Rampersaud E, Dahm P, Robertson C, et al. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged,50 years. BJU Int 2007;99:753-7.
26. Duffield AS, Lee TK, Miyamoto H, Carter HB, Epstein JI. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol 2009;182:2274-9.
27. van den Bergh RCN, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T, et al. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. BJU Int 2010;105:956-62.
28. Abaza R, Diaz LK, Jr, Laskin WB, Pins MR. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy. J Urol 2006;176: 2701-5.